USP vs EP Nicotine Standards: Key Differences Explained

Manufacturers selling into both the US and EU often treat USP and EP as interchangeable. They are not. The two pharmacopoeias do not even set the same acceptance range for nicotine content: the USP window is 98.0 to 102.0 percent and the Ph. Eur. window is 99.0 to 101.0 percent, so a batch can satisfy one monograph and fail the other on the headline number alone. Getting that wrong means rejected submissions, delayed launches, and reformulation costs that nobody budgeted for.

This is not an academic distinction. If you are sourcing pure nicotine for products that cross international borders, understanding where these standards align and where they diverge is a procurement requirement, not optional reading.

Quick Orientation

USP (United States Pharmacopeia) is published by the US Pharmacopeial Convention. Its monographs define identity, strength, purity, and quality for drug substances sold in the United States. USP standards are referenced throughout FDA regulatory frameworks, including PMTA submissions for tobacco products and NDAs/ANDAs for pharmaceutical nicotine products.

EP (European Pharmacopoeia) is published by the European Directorate for the Quality of Medicines (EDQM). EP monographs are legally binding for pharmaceutical products sold in EU member states and many countries that adopt EP standards, including Switzerland, Turkey, and numerous African and Asian nations that reference the EP. The EP carries legal weight under the EU TPD for nicotine-containing consumer products as well.

Both are serious. Neither is optional if you are selling pharmaceutical nicotine in their respective jurisdictions. And if you are selling into both markets, you need to understand both.

The One Comparison the Public Record Supports

That table is short on purpose. Why it is short is the most useful thing a buyer can learn about these two documents.

The USP figure is the definition line of the Nicotine monograph in USP-NF, which is the portion USP publishes outside its subscription. The Ph. Eur. figure is monograph 1452, published by the EDQM through Ph. Eur. online. Everything else in either monograph, every prescribed method, every chapter reference and every impurity limit, sits behind a paid subscription and cannot be quoted from a public source.

A pharmacopoeial limit quoted with no edition attached is not an auditable claim either. Before you write a number into a purchase specification, check it against the edition in force on the day you write it, and check it against the monograph rather than against a datasheet that paraphrases one.

Assay: Where the Two Standards Diverge

The USP monograph requires not less than 98.0 percent and not more than 102.0 percent of nicotine, calculated on the anhydrous basis. The Ph. Eur. requires 99.0 percent to 101.0 percent on the same basis. The European window is half as wide, and it sits entirely inside the American one.

That asymmetry has a direction, and the direction is what costs money. Material that satisfies the Ph. Eur. assay necessarily satisfies the USP assay. Material that satisfies the USP assay does not necessarily satisfy the Ph. Eur. one: a batch at 98.4 percent anhydrous is comfortably compliant USP nicotine and is out of specification in Europe. If you are buying against a US specification and expect to ship into the EU later, that is the gap you will find late.

Three things follow, and all three get reported wrongly in supplier literature.

The basis is anhydrous, not dried. Nicotine is a hygroscopic liquid. An anhydrous-basis result is corrected for the water the sample actually contains; it is not produced by drying the sample first. A COA that says "99.4%, dried basis" is not reporting the quantity either monograph is written against, and the water determination behind the correction belongs on the same certificate.

There is an upper limit as well as a lower one. A result of 101.6 percent is out of specification in Europe exactly as a result of 98.7 percent is, even though both sit inside the USP window. A number at the top of the range points to a standardisation or water-correction problem, not to unusually good material.

99.5 percent is not a pharmacopoeial figure. It is a supplier specification, set tighter than either compendial floor so that normal batch-to-batch variation still clears both with margin. The pure nicotine supplied through NicAlliance is specified at 99.5 percent and above for that reason. Treat "99.5%+" as a commercial commitment and treat the monograph windows as the compendial requirement. Both are real, they are not the same claim, and a supplier who quotes you 99.5 percent as the thing USP requires is telling you something about how carefully they read the monograph.

"Clearing the standard" and "being certified against the standard" are also two different things. Your COA needs to report results using the specific method prescribed by the monograph you are claiming compliance with.

For a broader explanation of what USP/EP grade nicotine means and why purity matters at a fundamental level, see our full explainer.

What the Subscription Hides, and What to Ask For Instead

Beyond that definition line, both monograph texts are subscription products. That is a legitimate commercial decision by USP and the EDQM, and it has a consequence buyers rarely think through: you cannot audit a compendial claim from public sources. Neither can most of the people writing the sales literature you are reading, which is why so much of it contradicts itself and why the same wrong assay figure has circulated for years.

You will find parameter-by-parameter tables of methods, chapter numbers and impurity limits for these two monographs all over the web, including in earlier versions of this article. Ours is gone, because the figures could not be traced back to the monograph texts, and a limit you cannot trace is not one to restate with a hedge in front of it. What follows is what can be established, and what to require in writing in place of the rest.

Related Substances

Both pharmacopoeias control the minor alkaloids and degradants that survive purification, and both treat the individual compounds as named entities rather than as an anonymous total. The USP side of this is publicly visible: the reference standards listed under the Nicotine monograph in USP-NF are Nicotine Bitartrate Dihydrate RS together with Nicotine Related Compound A through Nicotine Related Compound G RS. A pharmacopoeia does not commission, certify and sell seven related compound standards for a test that reports one lumped figure.

The limits attached to those compounds, and the chromatographic procedure each pharmacopoeia prescribes, are inside the paid text. Do not accept them secondhand, from us or from a supplier. Require instead that the COA:

• names the monograph and the edition it was tested against, on every line rather than only on the assay
• names the chapter or general method that produced each result
• reports each related compound as a measured value against its own limit, not as the word "complies"
• comes from a laboratory whose ISO 17025 scope actually covers those methods for this material

The last point is where qualification programmes usually stall. A laboratory equipped to certify against one pharmacopoeia is not automatically equipped to certify against the other, because the two bodies maintain separate official reference materials. USP Reference Standards and Ph. Eur. Chemical Reference Substances are not interchangeable; each has to be bought, qualified and stocked on its own. That shows up as a delay in getting a dual COA rather than as a failed result, which is why it is worth asking about before you commit to a launch date.

Optical Rotation

Nicotine from tobacco is S-(-)-nicotine and is strongly levorotatory. Synthetic nicotine made without a chiral step is racemic and close to optically inactive, so a rotation measurement is the cheapest screen available for racemic material. It will not detect blending with enantiopure synthetic S-nicotine, which is optically indistinguishable from the tobacco-derived molecule and needs a separate analysis.

Where a certificate reports rotation, insist that it prints the measured value together with the solvent and the concentration it was measured at, rather than the word "complies". Be sceptical of a rotation figure on a specification sheet with no dilution attached: the value usually quoted for undiluted nicotine is a physical constant of the neat liquid, and quoting it is not evidence of compendial compliance.

Elemental Impurities

Neither nicotine monograph contains an element-specific heavy metals test. This is the claim most often stated wrongly in nicotine specifications, so it is worth being exact about where the limits actually come from.

• USP retired its wet-chemistry test. General chapter 231 (Heavy Metals) was omitted from USP-NF with effect from 1 January 2018 and replaced by chapters 232 (Elemental Impurities: Limits) and 233 (Elemental Impurities: Procedures), which adopt the ICH Q3D framework and instrumental methods such as ICP-MS and ICP-OES. USP maintains a public elemental impurities update page tracking that work.
• Ph. Eur. did the same thing. The reference to general chapter 2.4.8 (Heavy metals) was deleted from monographs on substances for pharmaceutical use from the 9th Edition onward. Elemental impurities are now handled under general chapter 5.20 (Elemental impurities), which reproduces the principles of ICH Q3D, with determination under 2.4.20.

So on this parameter the two pharmacopoeias have converged on the same source document. What that document does is the part buyers get wrong.

ICH Q3D(R2) sets a permitted daily exposure (PDE) in micrograms per day for each element, and the PDE differs by route of administration. It does not set a parts-per-million limit for nicotine, or for any other single ingredient. A concentration limit only exists once you fix a daily dose. Q3D's Option 1 table does that by assuming a drug product daily intake of not more than 10 grams:

Read across the mercury row: the same element carries limits that differ by a factor of thirty depending on how the product is used. Anyone who quotes you "the pharmacopoeial limit" for lead or arsenic in nicotine as a single ppm number, with no route and no daily dose attached, has skipped the calculation that produces the number.

Ask for two things instead. First, the measured elemental impurity values for the batch, in µg/g, with the method named (ICP-MS under USP 233 or Ph. Eur. 2.4.20) rather than a pass/fail. Second, the supplier's elemental impurity risk assessment, which is what Q3D actually requires: an evaluation of which elements could plausibly enter the material from the soil, the process, the equipment and the container. You then apply your own route and daily dose to decide whether those values keep your finished product inside the PDE.

One more thing worth stating plainly, because it changes who carries the burden. Nicotine pouches and e-liquids are tobacco products, not drug products, so ICH Q3D does not apply to them as a matter of law. It is the framework the industry has borrowed because it is the only rigorous one available and reviewers recognise it. That means the justification for your limits is yours to make, not something you inherit by buying pharmacopoeial-grade material.

Your testing laboratory still needs to be explicit about which protocol it is running. Sample preparation, reference material and validation requirements differ between USP 233 and Ph. Eur. 2.4.20 even though the underlying PDEs are the same.

The source of the nicotine matters enormously here. Tobacco grown in regions with contaminated soil concentrates heavy metals during cultivation. Suppliers with contract farming programs control soil quality from the start. Spot-market sourcing introduces heavy metal variability that no amount of downstream testing can fully mitigate.

Residual Solvents

Both control residual solvents against the ICH Q3C limits, through different chapters:

• USP carries the limits in general chapter 467, which applies across USP articles rather than being written into any one monograph.
• Ph. Eur. carries them in general chapter 5.4, with the gas chromatographic procedure in 2.4.24, reached through the general monograph 2034 on substances for pharmaceutical use.

The classification system is the same on both sides. Class 1 solvents (benzene, carbon tetrachloride) should not be used at all; where their use is unavoidable, Q3C caps them at 2 ppm and 4 ppm respectively. Class 2 solvents have concentration limits. Class 3 solvents (ethanol, acetone) are low-toxicity and permitted at higher levels.

The familiar Class 2 numbers carry the same buried assumption as the elemental impurity numbers above. Hexane at 290 ppm and dichloromethane at 600 ppm are Option 1 values, derived from permitted daily exposures of 2.9 mg per day and 6.0 mg per day on the assumption of a 10 gram daily product intake. If your product's daily intake is different, so is the concentration limit. Q3C provides Option 2 precisely so you can calculate against your actual dose.

Your testing lab needs to run the specific method for the standard you are certifying against. A residual solvent result generated using Ph. Eur. 2.4.24 methodology may not be accepted as evidence of USP 467 compliance, and vice versa, even though the permissible limits are identical. This is not bureaucratic pedantry. Different sample preparation and analytical conditions can produce different results on the same material.

Water Content

An anhydrous-basis assay is meaningless without a water figure, so a water determination sits behind the number in both monographs. That makes it more important than its difficulty suggests. A COA that reports an anhydrous-basis assay without printing the water result it was corrected with has left out half the calculation, whichever monograph it names, and the chapter that produced the water figure should be named alongside it.

Which Standard Do You Need?

US market: USP compliance required for pharmaceutical products. Strongly recommended for e-liquid and nicotine pouch products to support PMTA submissions. The FDA does not technically require USP-grade nicotine for tobacco products, but applicants who use it have a clearer path through the review process because the quality parameters are already defined and accepted.

EU market: Ph. Eur. compliance required for pharmaceutical products. Recommended for TPD-notified products. Several EU member states have gone beyond the TPD minimum and impose pharmaceutical-grade requirements on e-liquid ingredients.

UK market: EP standards adopted. The post-Brexit regulatory framework largely mirrors TPD requirements. The UK MHRA references EP monographs for pharmaceutical-grade nicotine.

Both markets: Dual USP/EP compliance. This is the practical choice for any manufacturer with international ambitions. It also future-proofs your supply chain, since regulatory requirements tend to tighten over time, not loosen.

Other markets: Many countries reference either USP or EP as their pharmacopoeial standard. Japan uses JP (Japanese Pharmacopoeia) with its own nicotine monograph. Australia references both USP and EP. Countries in the Gulf Cooperation Council typically reference EP. Know your target market's pharmacopoeial framework before you source.

The Case for Dual Compliance

On assay, the Ph. Eur. window sits inside the USP one, so pure nicotine that meets the Ph. Eur. content limits meets the USP content limits as well. That is the one parameter where the public record lets you reason that way, and content is also the easiest parameter to hit. On everything else you would be guessing, and regulators do not accept guesses. You need testing and certification against both monographs, using the specific methods each prescribes.

Dual compliance also simplifies your supply chain. Rather than maintaining separate inventories of USP-grade and EP-grade nicotine, you stock one product that serves both markets. This reduces warehousing costs, simplifies inventory management, and eliminates the risk of using the wrong grade in production. For manufacturers producing nicotine polacrilex or nicotine bitartrate dihydrate for multiple markets, dual compliance at the raw material level cascades into dual compliance at the finished product level.

Dual certification costs something, because it means running each monograph's own procedures and stocking each pharmacopoeia's own reference materials rather than one set. Ask your supplier to quote the difference rather than assuming it. Whatever it comes to, it is bounded and knowable in advance, which is not true of discovering after a European launch commitment that your USP-only material has never been tested against the Ph. Eur. limits.

Common Pitfalls

Assuming USP equals Ph. Eur. They do not even share an assay window: USP runs 98.0 to 102.0 percent anhydrous and the Ph. Eur. runs 99.0 to 101.0 percent. USP compliance does not guarantee Ph. Eur. compliance. Always request testing against the specific standard your market requires.

Accepting a purity number with no basis and no method. A result of 99.7% is incomplete without knowing whether it is on the anhydrous basis, what the water content was, and which chapter's procedure produced it. Insist on COAs that name the monograph and the chapter for every line.

Taking a compendial number from a datasheet. Apart from the USP definition line, both monograph texts are subscription publications. When a supplier quotes you a chapter number or an impurity limit, ask which edition it came from and expect them to be able to produce it. A figure that has been copied between sales sheets for years is not a specification, and the 99.0 to 101.0 percent assay range widely attributed to USP is exactly that: the Ph. Eur. number wearing the wrong label.

Quoting a ppm limit for heavy metals as if it were compendial. Neither monograph contains one. ICH Q3D limits are permitted daily exposures in micrograms per day, and they convert to a concentration only once a route and a daily dose are fixed. Ask for measured values and the risk assessment, not a pass/fail against a number nobody can source.

Not verifying reference standards. Both pharmacopoeias require identification against official reference materials. USP Reference Standards and Ph. Eur. Chemical Reference Substances are not interchangeable. Your testing lab needs the correct one for the monograph it is certifying against.

Frequently Asked Questions